Additional Information
Market:AIM
Sector:Technology
EPIC:SEE
Latest Price: 3.00  (9.09% Ascending)
52-week High:3.88
52-week Low:1.88
Market Cap:12.41M
1 year chart
digital-look imported chart image
1 day chart
digital-look imported chart image
Seeing Machines Full Seeing Machines profile here

Seeing Machines (LON: SEE) is an award winning technology company with a focus on vision based human machine interfaces. Seeing Machines technology platform is based on world-leading computer vision processing technologies that allow machines to see and track human faces and certain facial features. These technologies enable the development of new cutting edge products and applications, ranging from devices that improve road safety & save lives, to those that help manage eye disease and prevent loss of eyesight.

The company’s focus is on deploying its computer vision technologies, worldwide, in:

  • Driver/operator safety products for transport markets through the DSS product range;
  • The TrueField Analyzer® (TFA) product for vision testing devices for healthcare markets;
  • New products in a range of markets including sports, entertainment, robotics and security through our faceAPI product; and
  • Human performance measurement through our faceLAB® product.

Seeing Machines makes maiden interim profit, to launch FTFA product mid-2009

Wednesday, March 11, 2009
Seeing Machines makes maiden interim profit, to launch FTFA product mid-2009

Computer vision technology company  Seeing Machines Ltd made a maiden pretax profit in the first half to end-December 2008 of A$358,682 after a A$430,155 loss a year earlier, while revenue rose to A$3.28 million from A$1.31 million.

The group is now generating revenue from three product lines: the driver attention and fatigue monitoring system Driver State Sensor (DSS), the face-tracking product faceAPI, and the faceLAB eye tracking product for research applications.

It is planning to commercially launch its clinical eye testing device TrueField Analyzer (TFA) in mid-2009.

Chief Executive Nick Cerneaz said “With the release of faceLAB 5 last month, the growing interest from product developers in our faceAPI software, continued strong interest in the DSS and the release of TFA mid-year 2009, we believe the company is well placed for future growth.”

It has largely completed the development work required to bring the TFA to market. Seeing Machines’ partners at the Australian National University Research School of Biological Sciences are completing their research program.

Although it is pleased with the performance of the period under review the company remains cautious going forward given the recent slowdown in revenue growth in the DSS business due to the global economic downturn and expects that in the second half of the financial year revenue growth may be harder to achieve.

With this in mind it announced on February 18 2009 the restructure of Seeing Machines in order to put the company on as sound a footing as possible to minimise the effects of this downturn, it added.

Edison Investment Reseach issued a note on Seeing Machines today, saying the current valuation looks intriguing given the potential to leverage the company’s intellectual property into large corporate sales.
Seeing Machines is a research client of Edison.

No investment advice

The Company is a publisher and is not registered with or authorised by the Financial Services Authority (FSA). You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.